



**For Immediate Release**  
**June 5, 2013**

**Contacts:** Steven Grossman 1-301-539-9660  
Diane Dorman 202-588-5700

## **House Appropriations Committee Mark-up “A Step in the Right Direction,” Will Seek Additional FDA Funding**

-----  
Under House Bill, FDA’s FY 14 Funding Would Increase Almost \$100M from Post-Sequester FY 13 Levels, Still Below FY 12 Funding

WASHINGTON, D.C., June 5, 2012 –The Alliance for a Stronger FDA expressed appreciation for the House Appropriations Committee’s clear prioritization of the U.S. Food and Drug Administration in the FY 14 funding process. However, further increases are still needed to support FDA’s critical mission.

"In this time of continuing deficit reduction, we understand the difficult fiscal environment under which the House is operating," said Diane Dorman, President of the Alliance and Vice President for Policy at the National Organization for Rare Disorders (NORD). "Chairman Robert Aderholt and Ranking Member Sam Farr’s decision to exceptionalize FDA--by proposing an FY 14 funding level that is nearly \$100 million above where the agency was left after the FY 13 sequester—is a positive step in the right direction."

Dorman added: “We believe that FDA's funding needs to be increased further—well above the FY 12 level--to reflect the agency's vast public health responsibilities and continually increasing workload. If the FDA does not have the resources to fulfill its mission, there is no other Federal, state or private agency that provides a fallback. ”

Under the proposed legislation adopted by the House Appropriations Committee this morning, FDA’s appropriated funding would be about \$22 million below the agency’s FY 12 funding level of \$2.507 billion. (See chart on page 2 for various comparisons).

"Alliance members remain committed to continuing our efforts to assure that FDA is adequately funded." said Kasey K. Thompson, Pharm.D., M.S., Vice President of the Alliance and Vice President, Office of Policy, Planning and Communications, American Society of Health-System Pharmacists. “It is a national priority for FDA to have the resources it needs to meet the challenges of a changing global economy and medical advances."

The importance of FDA and its regulated industry to the American economy is detailed in the Alliance’s white paper: [FDA: A Cornerstone of America’s Economic Future](#).

The Alliance’s nearly 200 members are comprised of consumer, patient, professional and research groups, companies, trade associations, and individuals who support increased appropriated funding for FDA. The Alliance is the only multi-stakeholder group that advocates for increasing resources at FDA to match the agency’s responsibilities. More information about the Alliance can be found at [www.StrengthenFDA.org](http://www.StrengthenFDA.org).

###



JUNE 5, 2013 a.m. DRAFT PRELIMINARY ANALYSIS

**House Appropriations Committee Mark for FY 14 Agriculture/FDA Funding**

**---Budget Authority Appropriations for FDA (does not include user fees)---**

Compared to FY 12, FY 13 Post-Sequester, the President’s FY 14 Request and the Base Used by the House

<b>Function</b> Note: budget authority only, by center; no user fees	<b>FY 12</b>	<b>FY 13</b> Post-rescission, post-sequester	<b>FY 14</b> President’s Request	<b>FY 13</b> Enacted Level ---- Used as Base by the House	<b>FY 14</b> <u>House Approps Committee Mark 6/5/13</u>
Food	\$ 867 million	\$ 805 million	\$ 883 million	\$ 848 million	<b>\$ 861 million</b>
Human Drugs	\$ 478 million	\$ 438 million	\$ 466 million	\$ 462 million	<b>\$ 465 million</b>
Biologics	\$ 212 million	\$ 195 million	\$ 211 million	\$ 205 million	<b>\$ 205 million</b>
Animal Drugs/Feed	\$ 138 million	\$ 127 million	\$ 142 million	\$ 134 million	<b>\$ 136 million</b>
Devices & Radiological Health	\$ 323 million	\$ 296 million	\$ 321 million	\$ 313 million	<b>\$ 313 million</b>
Natl. Ctr. For Toxicological Research	\$ 60 million	\$ 55 million	\$ 59 million	\$ 58 million	<b>\$ 58 million</b>
HQ, Officer. of Commissioner & Other	\$ 154 million	\$ 151 million	\$ 173 million	\$ 159 million	<b>\$ 165 million</b>
Rent & Facilities Cost	\$ 266 million	\$ 269 million	\$ 295 million	\$ 282 million	<b>\$ 282 million</b>
<b>SUBTOTAL, Salaries &amp; Expenses</b>	<b>\$ 2.497 billion</b>	<b>\$ 2.335 billion</b>	<b>\$2.549 billion</b>	<b>\$ 2.461 billion</b>	<b>\$2.485 billion</b> <i>Note: \$24M over base</i>
Building and Facilities Repair	\$ 9 million	\$ 5 million	\$ 9 million	\$ 5 million	<b>No dollars provided</b>
Food and Drug Safety Supplemental—No-Year		\$ 49 million			
<b>All BA appropriations Total (no user fees)</b>	<b>\$ 2.507 billion</b>	<b>\$ 2.389 billion</b>	<b>\$2.558 billion</b>	<b>\$2.466 billion</b>	<b>\$2.485 billion</b>

**Not all numbers add due to rounding.**

**NOTE:** Total spending for FDA in the last column is an accurate reflection of the House position. The budget authority appropriations (BA) allocations by Center are derived numbers—total appropriations by center, minus user fees allocated to centers in accordance with the President’s request.

**Steven Grossman**, phone: (301) 539-9660 email: [sgrossman@StrengthenFDA.org](mailto:sgrossman@StrengthenFDA.org)  
**Ladd Wiley**, phone: (202) 887-4083 email: [lwiley@StrengthenFDA.org](mailto:lwiley@StrengthenFDA.org)